Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Roos S G Sablerolles, Abraham Goorhuis, Corine H GeurtsvanKessel, Rory D de Vries, Anke L W Huckriede, Marion P G Koopmans, Melvin Lafeber, Douwe F Postma, Debbie van Baarle, Leo G Visser, Virgil A S H Dalm, Neeltje A Kootstra, Wim J R Rietdijk, P Hugo M van der Kuy*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

49 Downloads (Pure)
Original languageEnglish
Article number753319
Number of pages4
JournalFrontiers in Immunology
Volume12
DOIs
Publication statusPublished - 24-Sep-2021

Keywords

  • SARS-CoV-2
  • COVID-19
  • Homologous vaccination regimen
  • Heterologous vaccine regimen
  • randomized clinical trial
  • Ad26.Cov2.S
  • BNT162.b2
  • mRNA1273 & nbsp;
  • REACTOGENICITY

Cite this